Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVICO longitudinal follow-up of SARS-CoV-2 immunity in immunocompromised populations in Belgium
2024-518098-33-01Phase 4Authorised
- Sponsor
- Sciensano
- Start
- Nov 2024
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of raxtozinameran and bretovameran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Sciensano. Planned start Nov 2024; status: authorised.
02
Drugs
raxtozinameranbretovameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2024-518098-33-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518098-33-01.